An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma.

ABSTRACT: The advent of dose intensified interval compressed therapy has improved event-free survival for patients with localized Ewing sarcoma (EwS) to 78% at 5 years. However, nearly a quarter of patients with localized tumors and 60-80% of patients with metastatic tumors suffer relapse and die of disease. In addition, those who survive are often left with debilitating late effects. Clinical features aside from stage have proven inadequate to meaningfully classify patients for risk-stratified therapy. Therefore, there is a critical need to develop approaches to risk stratify patients with EwS based on molecular features. Over the past decade, new technology has enabled the study of multiple molecular biomarkers in EwS. Preliminary evidence requiring validation supports copy number changes, and los

SUBMITTER: Shulman DS 

PROVIDER: S-EPMC9482616 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature